Apatinib can increase autophagy and apoptosis in osteosarcoma by targeting the VEGFR2-mediated signal transducer and activator of transcription 3 (STAT3)/B-cell lymphoma-2 (Bcl-2) pathway [14]. Here, KDR is linked to osteosarcoma.